August 17, 2021 –
The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for additional doses of mRNA COVID-19 vaccines for moderately to severely immunocompromised people. People with immunocompromising conditions or who take immunosuppressive medications or therapies are at increased risk for severe COVID-19. Studies indicate that some immunocompromised people have a reduced immune response following a primary COVID-19 vaccine series compared to vaccine recipients who are not immunocompromised. Studies have further demonstrated that an additional mRNA COVID-19 vaccine dose after an initial 2-dose primary mRNA COVID-19 vaccine series in some immunocompromised populations may enhance immune response.
During this COCA Call, presenters will discuss the current data on COVID-19 vaccines in immunocompromised people; the role of additional doses of mRNA COVID-19 vaccines, patients who should be considered to receive these additional COVID-19 vaccine doses, results from the August 13, 2021, Advisory Committee on Immunization Practices (ACIP) meeting, and CDC’s guidance on additional COVID-19 doses in immunocompromised people.
US: +1 669 254 5252
or +1 646 828 7666
or +1 669 216 1590
or +1 551 285 1373
US: +16692545252,,1602130331#,,,,*549822# or +16468287666,,1602130331#,,,,*549822#
Webinar ID: 160 213 0331